Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer

Trial Profile

A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2018

At a glance

  • Drugs Selinexor (Primary)
  • Indications Carcinoma; Endometrial cancer
  • Focus Therapeutic Use
  • Acronyms SIENDO
  • Sponsors Karyopharm Therapeutics
  • Most Recent Events

    • 14 Dec 2018 Planned number of patients changed from 161 to 192.
    • 17 May 2018 This trial expected to enrol 160 patients, according to Karyopharm Therapeutics website. (http://investors.karyopharm.com/node/10781/html)
    • 17 May 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top